Skip to main content
ASND
NASDAQ Life Sciences

EVP Sells All Direct Holdings for $4.6M Amidst Positive Company News

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$237.65
Mkt Cap
$14.824B
52W Low
$150.89
52W High
$250.74
52W Position info
57% above low
Off High info
5.2% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ASND sits 57% above its 52-week low of $150.89.

Summary

An EVP at Ascendis Pharma A/S fully liquidated their direct stock holdings for $4.6 million, a notable insider sale occurring during a period of strong positive company developments.


Key Events · Ownership and Investor Activity · ASND

  • EVP Sells All Direct Holdings

    Flemming Steen Jensen, an Executive Vice President, sold 19,460 ordinary shares for a total of $4,641,021.

  • Complete Liquidation of Direct Shares

    Following this transaction, the EVP holds zero direct shares in the company, indicating a full disposition of their direct ownership.

  • Sale Amidst Positive Company Momentum

    This insider sale occurs shortly after Ascendis Pharma reported strong Q1 2026 net profit, FDA approvals for YUVIWEL, and positive trial results for other therapies.


Analysis · ASND · Life Sciences

An Executive Vice President (EVP) at Ascendis Pharma A/S sold all of their direct holdings, totaling over $4.6 million, just days after the company reported strong Q1 2026 earnings and recent FDA approvals. While the transaction represents a small percentage of the company's large market capitalization, the complete disposition of an insider's direct shares can signal a lack of personal conviction in the company's future prospects from that individual.

How filings like this one have moved

In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ASND was trading at $237.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $150.89 to $250.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ASND - Latest Insights

ASND
Oct 16, 2026, 7:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $226.62
Real-time Price: $225.25 info
Change: -$1.37 (-0.60%) info
Market Cap: $14.05B info
ASND
Sep 14, 2026, 6:34 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $267.00
Real-time Price: $225.25 info
Change: -$41.75 (-16%) info
Market Cap: $14.05B info
ASND
Sep 14, 2026, 6:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $263.15
Real-time Price: $225.25 info
Change: -$37.90 (-14%) info
Market Cap: $14.05B info
ASND
Sep 10, 2026, 9:52 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $262.10
Real-time Price: $225.25 info
Change: -$36.85 (-14%) info
Market Cap: $14.05B info
ASND
Sep 09, 2026, 5:21 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $260.81
Real-time Price: $225.25 info
Change: -$35.56 (-14%) info
Market Cap: $14.05B info